Fitchburg, WI, United States of America

Darren H Wakefield

USPTO Granted Patents = 58 

 

 

Average Co-Inventor Count = 4.9

ph-index = 10

Forward Citations = 485(Granted Patents)

DiyaCoin DiyaCoin 0.36 


Inventors with similar research interests:


Location History:

  • Madison, WI (US) (2006 - 2008)
  • Fitchburg, WI (US) (2006 - 2024)

Company Filing History:


Years Active: 2006-2025

where 'Filed Patents' based on already Granted Patents

58 patents (USPTO):

Sure! Here is the article about inventor Darren H Wakefield:

Title: Innovator Spotlight: Darren H Wakefield, Pioneering RNAi Therapeutics

Introduction:

Darren H Wakefield, a prolific inventor based in Fitchburg, WI, has made significant contributions to the field of RNA interference (RNAi) therapeutics. With an impressive portfolio of 54 patents, Wakefield has been at the forefront of developing innovative solutions for improving siRNA bioavailability and inhibiting gene expression in cancers.

Latest Patents:

Among his latest patents, Wakefield has introduced groundbreaking compositions for enhancing siRNA delivery by utilizing GalNAc moieties. These compositions can be conjugated to oligonucleotides like small interfering RNAs, paving the way for more effective treatments. Additionally, his work on inhibiting gene expression of Hif2alpha (EPAS1) gene showcases novel RNAi triggers and pharmaceutical compositions for combatting cancer at the genetic level.

Career Highlights:

With a distinguished career, Wakefield has held key roles at Arrowhead Pharmaceuticals, Inc. and Arrowhead Madison, Inc. These positions have allowed him to translate his innovative research into tangible solutions that have the potential to revolutionize targeted therapies for various diseases.

Collaborations:

Throughout his career, Wakefield has collaborated closely with esteemed colleagues such as David B Rozema and David L Lewis. Their synergistic efforts have led to the development of cutting-edge technologies in the field of RNAi therapeutics, pushing the boundaries of what is possible in precision medicine.

Conclusion:

Darren H Wakefield's pioneering work in RNAi therapeutics exemplifies the spirit of innovation and dedication to advancing healthcare solutions. His patents and collaborations underscore his commitment to driving meaningful change in the fight against complex diseases like cancer. Wakefield's contributions continue to shape the landscape of biomedical research, offering hope for more targeted and effective treatment options in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…